HDL-Targeting Therapeutics: Past, Present and Future

Author(s): Emile Zakiev, Ma Feng, Vasily Sukhorukov, Anatol Kontush*.

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 8 , 2017

Abstract:

Large-scale epidemiological studies firmly established the association between low plasma levels of high-density lipoprotein-cholesterol (HDL-C) and elevated risk of cardiovascular disease. This relationship is thought to reflect the key biological function of HDL, which involves reverse cholesterol transport from the arterial wall to the liver for further excretion from the body. Other aspects of the cardioprotective HDL functionality include antioxidative, anti-inflammatory, anti-apoptotic, anti-thrombotic, vasodilatory, anti-infectious and antidiabetic activities. Over the last decades, wide interest in HDL as an athero- and cardioprotective particle has resulted in the development of HDL-C raising as a therapeutic approach to reduce cardiovascular risk. Several strategies to increase circulating HDL-C concentrations were developed that primarily included use of niacin and fibrates as potent HDL-C raising agents. In the statin era, inhibition of cholesteryl ester transfer protein, infusion of artificially reconstituted HDL and administration of apolipoprotein A-I mimetics were established as novel approaches to raise HDL-C. More recently, other strategies targeting HDL metabolism, such as upregulation of apolipoprotein A-I production by the liver, were added to the list of HDL therapeutics. This review summarises current knowledge of novel HDL-targeting therapies and discusses perspectives of their use.

Keywords: Atherosclerosis, apoA-I, cardiovascular disease, CETP, HDL, lipoprotein, miRNA, rHDL.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 23
ISSUE: 8
Year: 2017
Page: [1207 - 1215]
Pages: 9
DOI: 10.2174/1381612822666161027153140
Price: $65

Article Metrics

PDF: 48
HTML: 8
EPUB: 1